Results 171 to 180 of about 40,504 (198)

Efavirenz

Reactions Weekly, 2002
openaire   +2 more sources

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Lancet, The, 2011
jean-michel Molina, Adriano Lazzarin
exaly  

Efavirenz

Reactions Weekly
  +4 more sources

Efavirenz

Reactions Weekly, 2009
openaire   +2 more sources

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Lancet, The, 2009
Jeffrey L Lennox, Adriano Lazzarin, José Valdez Ramalho Madruga   +2 more
exaly  

Efavirenz

Reactions Weekly, 2004
openaire   +1 more source

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Lancet, The, 2011
Bonaventura Clotet, Kiat Ruxrungtham
exaly  

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Lancet, The, 2012
Paul E Sax
exaly  

Efavirenz

Reactions Weekly, 2021
openaire   +1 more source

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

New England Journal of Medicine, 2019
Bruno Spire, Sandrine Leroy, Sylvie Boyer   +2 more
exaly